Bioforum C.D.M.C
Bioforum C.D.M.C is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Sponsor Bioinvent International AB
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 12 centers in Europe and the United States, of which 8 centers enrolled participants.
- Forty-two participants were screened by 9 sites, and 35 participants were enrolled over approximately 16 months.
- The planned Phase 2a part was not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations of Interest
Sponsor Elgan Pharma Ltd.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Open-label, Single-arm, Multicenter, Historical Control Study to Evaluate ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Sponsor Electra Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the safety of EscharEx in debridement of Venous Leg Ulcers (VALUE)
Sponsor Mediwound Ltd.
- Start (EU)
- Latest update
- Estimated end
A Multi-Center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Sponsor Elgan Pharma Ltd.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
Sponsor Ferrer Internacional S.A.
- Start (EU)
- Latest update
- Estimated end
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.
Sponsor Polypid Ltd.
- Start (EU)
- Latest update
- Estimated end
A 60 month, single-arm, proof-of-concept study to induce allogeneic tolerance in deceased donor liver transplant recipients using siplizumab, an anti-CD2 antibody in combination with cyclophosphamide and splenectomy.
Sponsor Itb-Med AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Bioforum C.D.M.C?
The 2026-10-09 snapshot links Bioforum C.D.M.C to 10 distinct CTIS trials. Recorded services include Data management, Statistical analysis, Unblinded Statistics for DMC meetings, Biostatiscs analysis and programming, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Bioforum C.D.M.C?
The most frequently recorded therapeutic areas are Gastroenterology, Dermatology, Gynecology, Nutrition. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Bioforum C.D.M.C conducted?
The linked trials record locations in 18 countries, including Spain, Italy, Germany, Sweden, Netherlands. These are trial locations, not confirmed office locations or countries where Bioforum C.D.M.C delivered services.
What can this page tell me about Bioforum C.D.M.C's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Bioforum C.D.M.C. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Bioforum C.D.M.C Ltd.